FindTrial
Sign In

200 mg pembrolizumab

BIOLOGICAL2 trials

Sponsors

Rakuten Medical, Inc., CytoDyn, Inc.

Conditions

Locally Advanced Cutaneous Squamous Cell CarcinomaMetastatic Colorectal Cancer (mCRC)Metastatic Cutaneous Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Phase 1

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Active, not recruitingNCT04305795
Rakuten Medical, Inc.Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma +1
Start: 2020-12-21End: 2027-06-30Updated: 2025-06-19

Phase 2

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
Active, not recruitingNCT06699836
CytoDyn, Inc.Metastatic Colorectal Cancer (mCRC)
Start: 2025-06-16End: 2028-03-01Updated: 2026-09-09

Related Papers

Editorial: Promising photosensitive agents for photodynamic therapy
Frontiers in Pharmacology2026-06-26
Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
Journal of Clinical Oncology2026-05-28
Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology2024-06-016 citations
83 Development of an image-based tumor microenvironment analysis coupled with peripheral flow cytometry reveals a distinct immune cell phenotype in responder patients in the phase 1b/2 study ASP-1929–181
Regular and Young Investigator Award Abstracts2023-10-31
1307 Development of a novel, cellular-level drug uptake quantification pipeline for accurate estimation of fluorescence-conjugated therapeutics: data from the phase 1b/2 open-label study ASP-1929–181
Regular and Young Investigator Award Abstracts2023-10-31
Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
Head & Neck2021-10-09156 citations
Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
EBioMedicine2021-05-011 citations